A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors Meeting Abstract
| Authors: | Sanbom, R. E.; Sharfman, W. H.; Segal, N. H.; Hodi, F. S.; Wolchok, J. D.; Urba, W. J.; Fox, B. A.; Topalian, S. L.; Pardoll, D. M.; Covello, K. L.; McDonald, D.; Kim, S. Y.; Gupta, A. K.; Wigginton, J. M.; Gajewski, T. |
| Abstract Title: | A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605404 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.TPS3110 |
| Notes: | Meeting Abstract: TPS3110 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work